Recently tech companies have been eager to go public and unload shares from the insiders to the less knowledgeable retail. Some have been successful, some have not. Zoom has seen success in their IPO … [Read more...] about Will Uber Make You Money In The Stock Market?
In this article I will discuss the following Zooms valuation & Finances; is 19 billion fair? Competitive landscapeRisks to investorsOther current opportunities for … [Read more...] about Is Zoom Really Worth $19 Billion?
Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?
Last Thursday, April 18th, Mustang Bio (MBIO) exploded for a whopping 84% gain despite closing well off its daily high. This move was in response to news that St. Jude Children's Research Hospital … [Read more...] about Will Mustang Bio Run?
This biotech stock sold off over 30% and now shows signs of life ahead of a catalyst. Two commercial products launched Q1 2019. First quarter sales numbers are highly anticipated by analysts … [Read more...] about MS Enters Another Biotech Stock
Some of the hottest stocks on the market are in the biotech sector. Of these, some of the hottest of the hot are in the NAFLD/NASH space. The reason being is the magnitude of disease prevalence and … [Read more...] about Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years
Zoom has announced that it will be going public on April 18th 2019. This has generated substantial hype and lead to a valuation of $36 per share tomorrow. In this article I will discuss; Potential … [Read more...] about Should You Buy The ZOOM IPO?
Whats Happening? Novavax Inc. (Nasdaq: NVAX) is getting attention lately as investors debate the potential of the company’s respiratory syncytial virus (RSV) vaccination “ResVax”, a proposed 1:20 … [Read more...] about NVAX At A Glance
You voted and we heard you. After my initial article on a few noteworthy results from AACR 2019, we asked you the subscribers to choose one of the four companies that you would like to learn more … [Read more...] about An In-Depth Assessment Of TG Therapeutics
Background Investors have recently been faced with many headwinds in the first half of 2019. With potential threats to Bulls positions constantly surfacing, 2019 has been volatile to say the least. … [Read more...] about Why I’m Bullish With Brexit